RxDoctor Payments Data

Aijaz Ahmed, MD

Internal Medicine · Urbana, OHNPI 1306911961

Payments from drug & device makers

$285in general payments, 2019–2025

Across 19 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$74
  • Johnson & Johnson$66
  • Lilly USA, LLC$43
  • VBI Vaccine (delaware) Inc.$23
  • Boehringer Ingelheim$19
  • Pfizer$13
  • plus $46 from 4 others

What the payments were for

  • Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis4$74
Johnson & Johnson(2 entities)5$66
Lilly USA, LLC3$43
VBI Vaccine (delaware) Inc.1$23
Boehringer Ingelheim1$19
Pfizer1$13
Amgen1$12
Novo Nordisk1$12
Sun Pharmaceutical Industries Inc.1$11
Merck1$11

How this compares

$285 in reported general payments places this provider in the 55th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$18,347
Medicare patients
132
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate211$171,745
EliquisApixaban118$115,037
XareltoRivaroxaban64$60,375
OzempicSemaglutide40$53,042
TrulicityDulaglutide33$38,149
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog49$27,988
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$27,307
MounjaroTirzepatide25$25,846
JanumetSitagliptin Phos/Metformin Hcl22$23,965
FarxigaDapagliflozin Propanediol32$21,318
Breo ElliptaFluticasone/Vilanterol34$21,226
RybelsusSemaglutide22$20,750
JardianceEmpagliflozin29$17,961
Spiriva HandihalerTiotropium Bromide17$17,100
Lantus SolostarInsulin Glargine,hum.Rec.Anlog115$14,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$11$195,710233 claims
PfizerEliquis$13$115,037118 claims
Novo NordiskOzempic, Rybelsus$12$73,79262 claims
Lilly USA, LLCTrulicity, Mounjaro$43$63,99558 claims
Johnson & JohnsonXarelto$66$60,37564 claims
Boehringer IngelheimJardiance, Spiriva Respimat$19$26,50745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Urbana

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →